



First Quarter 2023

Earnings Results

May 8, 2023





Safe Harbor Statements

This presentation has been prepared by NeoGenomics, Inc. (“we,” “us,” “our,” “NeoGenomics” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business, operations, and financial conditions of the Company. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “suggest,” “project,” “forecast,” “estimate,” “intend,” “plan,” “would,” “should” and “could,” and similar expressions or words, identify forward-looking statements. Although the Company believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Actual results could differ materially from those projected in the Company’s forward-looking statements due to numerous known and unknown risks and uncertainties. All forward-looking statements speak only as of the date of this presentation and are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date hereof.

Information contained in this presentation concerning our industry and the markets in which we operate, including our general expectations and market position, market opportunity and market size, is based on information from various sources, on assumptions that we have made that are based on such information and other similar sources and on our knowledge of, and expectations about, the markets for our service offerings. This information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

This presentation contains financial measures, such as adjusted EBITDA, adjusted gross margin and adjusted net income, which are considered non-GAAP financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). Adjusted EBITDA, adjusted gross margin and adjusted net income, unusual or other items that we do not consider indicative of our ongoing operating performance. The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables in this presentation. We cannot estimate or project these items and they may have a substantial and unpredictable impact on our results presented in accordance with GAAP.

Mission

We save lives by improving patient care.

Vision

We are becoming the world's leading cancer testing, information, and decision support company by providing uncompromising quality, exceptional service, and innovative solutions.



1st Quarter 2023 Highlights

- Total Revenue Increased **17%**
 - Clinical Revenue Increased **16%**
 - Pharma Revenue Increased **22%**
- Launched four new assays
 - **RaDaR®** for Clinical
 - Neo Comprehensive™ – Solid Tumor and Myeloid Disorders
 - NeoTYPE® DNA & RNA – Lung
- Improved testing turnaround time by 17% YoY


Revenue
Up 17%
To \$137M

Adj. Gross Profit
\$60M
Margin: 43.5%

8th Consecutive
Increase vs Prior
Year in Revenue
per Test

Adj. EBITDA
Up 63%
To -\$7M

Performance Continues to Improve



Description	1Q22	2Q22	3Q22	4Q22	1Q23
Revenue Growth Rate	1.4%	2.8%	6.1%	10.3%	17.1%
Adj Gross Profit Margin	36.8%	39.0%	41.7%	44.5%	43.5%


Our 2023 Strategic Priorities

Profitably Grow Our Core Business



- Grow Volume & Drive NGS Mix
- Expand & Optimize Commercial Organization
- Improve Turnaround Times

Accelerate Advanced Diagnostics



- Launch New Innovative Products
 - RaDaR (MRD)
 - Neo Comprehensive (NGS)
- Continue to Improve Pharma Growth & Profitability
- Focus on Enterprise Data Strategy

Drive Value Creation



- Increase Productivity & Efficiency
- Manage G&A Spend; Re-Invest in Strategic initiatives
- Enhance Automation & Digital Implementation
- Drive Revenue Cycle Management

Strong Q1 Execution Against 2023 Priorities



Profitably Grow the Core Business

- Strong Clinical volumes across all modalities, including NGS
- Strong growth in revenue per test
- Clinical salesforce expansion and optimization is ongoing
- Q1 set record for highest volume of testing per quarter in Company history



Accelerate Advanced Diagnostics

- Launched RaDaR (MRD) in four indications
- Expanded NGS portfolio offering with three new tests
- Completed MolDx submission for RaDaR in Breast cancer; two additional indications by year-end
- Completed Pharma & Informatics salesforce buildout



Drive Value Creation

- 17% improvement in turnaround time while processing significant increase in test volume
- Digital transformation is underway
- Generated significant operating leverage converting 59% of revenue growth to AEBITDA

First Quarter 2023 Financial Results

1st Quarter Clinical Services Results

- Revenue Grew 16.3% to \$114.9M
- Revenue per Test Improved 8.4% Due to Mix and Pricing
- Volume Increased 7.3%
- Beginning to See the Benefits of Investments Made in Field Resources in 2022




\$Millions	Revenue			
	Q2	Q3	Q4	Q1
2021 Revenue*	\$101.4	\$102.2	\$104.1	-
2022 Revenue	\$105.6	\$106.2	\$108.2	\$98.8
2023 Revenue	-	-	-	\$114.9
Growth %	4%	4%	4%	16%

*2021 revenue excludes COVID-19

1st Quarter Clinical Services Revenue per Test


- 8th Consecutive Quarter of Revenue per Test Growth
- Revenue per Test Increased 8% over Prior Year to \$402
- Focused on Higher-Value Tests
- Positive Contributions from Strategic Reimbursement Initiatives



Revenue per Test				
\$Dollars	<u>Q2</u>	<u>Q3</u>	<u>Q4</u>	<u>Q1</u>
2021 Rev/Test	\$360	\$375	\$383	-
2022 Rev/Test	\$387	\$392	\$389	\$371
2023 Rev/Test	-	-	-	\$402
Growth %	7%	5%	2%	8%

1st Quarter Pharma Services Results

- Continued Strong Revenue Growth of 22% to \$22M
- Gross Margin Improved 620 bps, representing the Third Consecutive Quarter of 500 bps+ of Improvement
- Continuing to Build Momentum with RaDaR (MRD) Pipeline



Revenue				
\$Millions	<u>Q2</u>	<u>Q3</u>	<u>Q4</u>	<u>Q1</u>
2021 Revenue	\$20.3	\$19.1	\$21.7	-
2022 Revenue	\$19.4	\$22.6	\$30.5	\$18.4
2023 Revenue	-	-	-	\$22.4
Growth %	-4%	18%	41%	22%

1st Quarter Income Statement

Income Statement In \$Millions	1Q23	%vPY
Clinical Services	114.9	16.3%
Pharma Services	22.4	21.6%
Total Net Revenue	137.2	17.1%
Cost of Revenue	82.4	4.4%
Adjusted Gross Profit	59.7	38.5%
Gross Margin (excl. Amort.)	43.5%	671bps
Sales & Marketing	16.3	-0.2%
as % of Revenue	11.8%	-206 bps
General & Administrative	61.5	-7.1%
as % of Revenue	44.9%	-1169 bps
Research & Development	7.4	-4.1%
as % of Revenue	5.4%	-119 bps
Restructuring Charges	4.7	100.0%
Total Operating Expenses	89.9	-0.4%
Loss From Operations	-35.1	32.6%
Net Income/Loss	-30.8	37.7%
Deprec. and Amort.	17.8	5.6%
Interest/Taxes and Adjustments	5.8	-56.7%
Adjusted EBITDA	-7.1	62.6%
as % of Revenue	-5.2%	1104 bps

YoY Improvement in Revenue Growth, Gross Margin and Adjusted EBITDA

- **Revenue:** Highest Revenue Growth by Quarter Since Q2 of 2021. Drivers are increases in revenue per test, volume and Pharma Services revenue.
- **Adjusted Gross Profit:** Increased by 38.5% over prior year due to higher revenue driven by volume and pricing per test reductions in cost per test
- **Operating Expenses.** Declined 0.4% primarily driven by lower compensation costs.
- **Adjusted EBITDA.** Improved \$12 million versus prior year due to improvement in gross profit and lower operating expenses.

1st Quarter Balance Sheet

Balance Sheet In \$Millions	Mar-23	Dec-22
Cash and cash equivalents	275.6	263.2
Marketable securities, at fair value	142.3	174.8
Accounts receivable, net	118.8	119.7
Inventories	24.4	24.3
Prepaid assets	16.2	15.2
Other current assets	7.6	8.1
Total current assets	585.0	605.3
Property and equipment, net	102.8	102.5
Operating lease right-of-use assets	93.8	96.1
Intangible assets, net	399.5	408.3
Goodwill	522.8	522.8
Other assets	5.3	5.1
Total non-current assets	1,124.2	1,134.7
Total Assets	1,709.2	1,740.0
Accounts payable and other current liabilities	79.6	83.3
Current portion of equipment financing obligations	0.0	0.1
Current portion of operating lease liabilities	6.9	6.6
Total current liabilities	86.6	89.9
Convertible senior notes, net	536.0	535.3
Operating lease liabilities	67.3	69.0
Deferred income tax liabilities, net	31.7	34.8
Other long-term liabilities	13.0	13.1
Total long-term liabilities	648.1	652.1
Total Liabilities	734.7	742.0
Total stockholders' equity	974.5	998.0
Total Liabilities and Stockholders' Equity	1,709.2	1,740.0

- **Cash and Marketable Securities: \$418 million**
- **Cash Burn: \$20 million**
- **Financial Flexibility to Make Needed Investments to Drive Long-Term Sustainable Growth**



Revised 2023 Guidance

FY 2023 Expectations as of May 8, 2023

- Focusing on Long-term, Sustainable Revenue Growth
- Adjusted EBITDA Growth Exceeds Revenue Growth Due to Improving Gross Profit and Operating Leverage
- Continue to Invest in the Business and Our People
- Expect to Achieve Positive Adjusted EBITDA in 4th Quarter of 2023

9% – 11% Revenue Growth

FY: \$555 – \$565 Million

Up from \$545 - \$555 Million

54% – 63% Adjusted EBITDA Growth

FY: (\$22) to (\$18) Million

Up from (\$27) – (\$22) Million

Summary

- Q1 strong revenue growth at 17% and improved AEBITDA growth of 63% vs PY
- Four new product launches expand portfolio offering
- Key strategic initiatives gaining traction leading to positive financial performance
- Raising FY23 revenue guidance to 9-11% revenue growth and AEBITDA guidance to 54-63% growth
 - \$555--\$565 million and (\$22)--(\$18) million, respectively



Serving Patients.
Saving Lives.





© 2021 NeoGenomics Laboratories, Inc. All rights reserved.
All other trademarks are the property of their respective owners.
Rev. 05.08.23

Appendix

Balance Sheet

March 31, 2023

(unaudited, in thousands)

	(unaudited) March 31, 2023	December 31, 2022
ASSETS		
Current assets		
Cash and cash equivalents	\$ 275,609	\$ 263,180
Marketable securities, at fair value	142,306	174,809
Accounts receivable, net	118,842	119,711
Inventories	24,432	24,277
Prepaid assets	16,185	15,237
Other current assets	7,622	8,077
Total current assets	584,996	605,291
Property and equipment, net	102,845	102,499
Operating lease right-of-use assets	93,784	96,109
Intangible assets, net	399,477	408,260
Goodwill	522,766	522,766
Other assets	5,306	5,109
Total non-current assets	1,124,178	1,134,743
Total assets	\$ 1,709,174	\$ 1,740,034
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities		
Accounts payable and other current liabilities	\$ 79,634	\$ 83,278
Current portion of equipment financing obligations	38	70
Current portion of operating lease liabilities	6,934	6,584
Total current liabilities	86,606	89,932
Long-term liabilities		
Convertible senior notes, net	536,037	535,322
Operating lease liabilities	67,319	68,952
Deferred income tax liabilities, net	31,715	34,750
Other long-term liabilities	13,035	13,055
Total long-term liabilities	648,106	652,079
Total liabilities	\$ 734,712	\$ 742,011
Stockholders' equity		
Total stockholders' equity	\$ 974,462	\$ 998,023
Total liabilities and stockholders' equity	\$ 1,709,174	\$ 1,740,034

Income Statement, March 31, 2023

(unaudited, in thousands)

	Three Months Ended March 31,	
	2023	2022
NET REVENUE		
Clinical Services	\$ 114,869	\$ 98,791
Pharma Services	22,351	18,378
Total net revenue	137,220	117,169
COST OF REVENUE	82,406	78,937
GROSS PROFIT	54,814	38,232
Operating expenses:		
General and administrative	61,549	66,248
Research and development	7,395	7,713
Sales and marketing	16,259	16,299
Restructuring charges	4,684	—
Total operating expenses	89,887	90,260
LOSS FROM OPERATIONS	(35,073)	(52,028)
Interest (income) expense, net	(1,467)	1,301
Other expense (income), net	114	(168)
Loss before taxes	(33,720)	(53,161)
Income tax benefit	(2,925)	(3,753)
NET LOSS	<u>\$ (30,795)</u>	<u>\$ (49,408)</u>
NET LOSS PER SHARE		
Basic	\$ (0.25)	\$ (0.40)
Diluted	\$ (0.25)	\$ (0.40)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING		
Basic	125,026	123,630
Diluted	125,026	123,630

Statements of Cash Flows, March 31, 2023

(unaudited, in thousands)

	Three Months Ended March 31,	
	2023	2022
CASH FLOWS FROM OPERATING ACTIVITIES		
Net loss	\$ (30,795)	\$ (49,408)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	9,048	8,395
Amortization of intangibles	8,783	8,490
Non-cash stock-based compensation	4,758	12,103
Non-cash operating lease expense	2,330	2,653
Amortization of convertible debt discount and debt issue costs	715	706
Gain on sale of assets held for sale	—	(2,048)
Impairment of assets	923	—
Other adjustments	(31)	1,126
Changes in assets and liabilities, net	(8,423)	(11,057)
Net cash used in operating activities	(12,692)	(29,040)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of marketable securities	(6,756)	(16,167)
Proceeds from sales and maturities of marketable securities	40,425	36,438
Purchases of property and equipment	(9,927)	(8,219)
Net cash provided by investing activities	23,742	12,052
CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of equipment financing obligations	(32)	(346)
Issuance of common stock, net	1,411	6,403
Net cash provided by financing activities	1,379	6,057
Net change in cash and cash equivalents	12,429	(10,931)
Cash and cash equivalents, beginning of period	263,180	316,827
Cash and cash equivalents, end of period	\$ 275,609	\$ 305,896

Adjusted Gross Margin, March 31, 2023

(unaudited, in thousands)

	Three Months Ended March 31,		
	2023	2022	% Change
Clinical Services:			
Total revenue (GAAP)	\$ 114,869	\$ 98,791	16.3 %
Cost of revenue (GAAP)	\$ 67,292	\$ 65,267	3.1 %
Adjustments to cost of revenue ⁽⁵⁾	(4,264)	(4,264)	
Adjusted cost of revenue (non-GAAP)	<u>\$ 63,028</u>	<u>\$ 61,003</u>	3.3 %
Gross profit (GAAP)	\$ 47,577	\$ 33,524	41.9 %
Adjusted gross profit (non-GAAP)	\$ 51,841	\$ 37,788	37.2 %
Gross profit margin (GAAP)	41.4 %	33.9 %	
Adjusted gross profit margin (non-GAAP)	45.1 %	38.3 %	
Pharma Services:			
Total revenue (GAAP)	\$ 22,351	\$ 18,378	21.6 %
Cost of revenue (GAAP)	\$ 15,114	\$ 13,670	10.6 %
Adjustments to cost of revenue ⁽⁶⁾	(589)	(589)	
Adjusted cost of revenue (non-GAAP)	<u>\$ 14,525</u>	<u>\$ 13,081</u>	11.0 %
Gross profit (GAAP)	\$ 7,237	\$ 4,708	53.7 %
Adjusted gross profit (non-GAAP)	\$ 7,826	\$ 5,297	47.7 %
Gross profit margin (GAAP)	32.4 %	25.6 %	
Adjusted gross profit margin (non-GAAP)	35.0 %	28.8 %	
Consolidated:			
Total revenue (GAAP)	\$ 137,220	\$ 117,169	17.1 %
Cost of revenue (GAAP)	\$ 82,406	\$ 78,937	4.4 %
Adjustments to cost of revenue ⁽⁵⁾⁽⁶⁾	(4,853)	(4,853)	
Adjusted cost of revenue (non-GAAP)	<u>\$ 77,553</u>	<u>\$ 74,084</u>	4.7 %
Gross profit (GAAP)	\$ 54,814	\$ 38,232	43.4 %
Adjusted gross profit (non-GAAP)	\$ 59,667	\$ 43,085	38.5 %
Gross profit margin (GAAP)	39.9 %	32.6 %	
Adjusted gross profit margin (non-GAAP)	43.5 %	36.8 %	

⁽⁵⁾ Clinical Services cost of revenue adjustments for both the three months ended March 31, 2023 and 2022 includes \$4.3 million of amortization of acquired Inivata developed technology intangible assets.

⁽⁶⁾ Pharma Services cost of revenue adjustments for both the three months ended March 31, 2023 and 2022 include \$0.6 million of amortization of acquired Inivata developed technology intangible assets.

Adjusted EBITDA, March 31, 2023

(unaudited, in thousands)

	<u>Three Months Ended March 31,</u>	
	<u>2023</u>	<u>2022</u>
Net loss (GAAP)	\$ (30,795)	\$ (49,408)
<i>Adjustments to net loss:</i>		
Interest (income) expense, net	(1,467)	1,301
Income tax benefit	(2,925)	(3,753)
Depreciation	9,048	8,395
Amortization of intangibles	8,783	8,490
EBITDA (non-GAAP)	\$ (17,356)	\$ (34,975)
<i>Further adjustments to EBITDA:</i>		
Acquisition and integration related expenses	—	1,030
Non-cash stock-based compensation expense	4,758	12,103
Restructuring charges	4,684	—
Other significant (income) expenses, net ⁽⁴⁾	798	2,831
Adjusted EBITDA (non-GAAP)	<u>\$ (7,116)</u>	<u>\$ (19,011)</u>

⁽⁴⁾ For the three months ended March 31, 2023, other significant (income) expenses, net, includes CEO transition costs, fees related to a regulatory matter, and other non-recurring items. For the three months ended March 31, 2022, other significant (income) expenses, net, includes a gain on the sale of a building, fees related to the regulatory matter, CEO transition costs, and other non-recurring items.

Adjusted EBITDA, 2023 Guidance

(unaudited, in thousands)

GAAP net loss in 2023 will be impacted by certain charges, including: (i) expense related to the amortization of intangible assets, (ii) non-cash stock based compensation, (iii) restructuring charges and (iv) other one-time expenses. These charges have been included in GAAP net loss available to stockholders and GAAP net loss per share; however, they have been removed from adjusted net loss and adjusted diluted net loss per share.

The following table reconciles the Company's 2023 outlook for net loss and EPS to the corresponding non-GAAP measures of adjusted net loss, adjusted EBITDA, and adjusted diluted EPS:

	Year Ended December 31, 2023	
	Low Range	High Range
Net loss (GAAP)	\$ (116,000)	\$ (108,000)
Amortization of intangibles	35,000	35,000
Non-cash stock-based compensation	27,000	26,000
Restructuring charges	7,000	7,000
Other one-time expenses	1,000	1,000
Adjusted net loss (non-GAAP)	(46,000)	(39,000)
Interest and taxes	(13,000)	(15,000)
Depreciation	37,000	36,000
Adjusted EBITDA (non-GAAP)	<u>\$ (22,000)</u>	<u>\$ (18,000)</u>
Net loss per diluted share (GAAP)	\$ (0.91)	\$ (0.84)
<i>Adjustments to net loss per diluted share:</i>		
Amortization of intangibles	0.27	0.27
Non-cash stock-based compensation expenses	0.21	0.20
Restructuring charges	0.05	0.05
Other one-time expenses	0.01	0.01
Rounding and impact of diluted shares in adjusted diluted shares ⁽¹¹⁾	0.01	0.01
Adjusted diluted EPS⁽¹²⁾ (non-GAAP)	<u>\$ (0.36)</u>	<u>\$ (0.30)</u>
Weighted average assumed shares outstanding in 2023:		
Diluted shares (GAAP)	128,000	128,000
Options, restricted stock, and converted shares not included in diluted shares ⁽¹²⁾	—	—
Adjusted diluted shares outstanding (non-GAAP)	<u>128,000</u>	<u>128,000</u>

⁽¹¹⁾ This adjustment is for rounding and, in those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, also compensates for the effects of additional diluted shares included in adjusted diluted shares outstanding for the treasury stock impact of outstanding stock options and restricted stock and the if-converted impact of convertible notes.

⁽¹²⁾ For those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, this adjustment includes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive.